SSY Group (HK:2005) has released an update.
SSY Group Limited has announced successful approvals for its Ondansetron Hydrochloride Injection, which is used for reducing nausea and vomiting associated with cancer treatments and after surgery. The drug has passed the consistency evaluation by China’s National Medical Products Administration. The company aims to keep shareholders and potential investors updated with this significant milestone in its product development.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
